Erasca (ERAS) News Today $1.57 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 29 at 3:11 AM | americanbankingnews.comAffinity Asset Advisors LLC Acquires 842,088 Shares of Erasca, Inc. $ERASAugust 28 at 9:09 AM | marketbeat.comT. Rowe Price Investment Management Inc. Has $23.69 Million Stock Position in Erasca, Inc. $ERASAugust 26 at 4:49 AM | marketbeat.comWall Street Zen Downgrades Erasca (NASDAQ:ERAS) to SellAugust 25, 2025 | marketbeat.comErasca (NASDAQ:ERAS) Rating Lowered to "Sell" at Wall Street ZenAugust 24, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Erasca (ERAS)August 20, 2025 | theglobeandmail.comErasca (NASDAQ:ERAS) Receives Equal Weight Rating from Morgan StanleyAugust 20, 2025 | marketbeat.comErasca (NASDAQ:ERAS) Earns Equal Weight Rating from Morgan StanleyAugust 20, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for Erasca FY2025 EarningsAugust 19, 2025 | marketbeat.comMorgan Stanley Downgrades Erasca (ERAS)August 19, 2025 | msn.comErasca downgraded to Equal Weight from Overweight at Morgan StanleyAugust 17, 2025 | msn.comPromising Penny Stocks To Consider In August 2025August 14, 2025 | uk.finance.yahoo.comErasca (NASDAQ:ERAS) Posts Quarterly Earnings Results, Hits EstimatesAugust 14, 2025 | marketbeat.comErasca, Inc.: Erasca Reports Second Quarter 2025 Business Updates and Financial ResultsAugust 13, 2025 | finanznachrichten.deErasca files $500M mixed securities shelfAugust 12, 2025 | msn.comErasca Reports Progress and Financial Stability in Q2 2025August 12, 2025 | tipranks.comErasca Reports Second Quarter 2025 Business Updates and Financial ResultsAugust 12, 2025 | globenewswire.comErasca (ERAS) to Release Earnings on MondayAugust 5, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Buy" from BrokeragesAugust 4, 2025 | marketbeat.comErasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid TumorsAugust 1, 2025 | msn.comErasca, Inc. (NASDAQ:ERAS) Given Consensus Rating of "Buy" by AnalystsJuly 10, 2025 | marketbeat.comUSA News Group: Oncology Innovation Just Hit a Turning Point -- Here's What to WatchJune 30, 2025 | finanznachrichten.deErasca, Inc. (NASDAQ:ERAS) Given Consensus Recommendation of "Buy" by BrokeragesJune 15, 2025 | marketbeat.comWellington Management Group LLP Takes Position in Erasca, Inc. (NASDAQ:ERAS)June 7, 2025 | marketbeat.comFDA clears Erasca’s new cancer drug applicationsJune 3, 2025 | uk.investing.comErasca Announces Clearance Of IND Application By FDA For ERAS-4001June 3, 2025 | nasdaq.comErasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001June 2, 2025 | globenewswire.comTwo Sigma Investments LP Has $2.41 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 198,600 Shares of Erasca, Inc. (NASDAQ:ERAS)June 1, 2025 | marketbeat.comBank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)May 30, 2025 | marketbeat.comErasca to Present at Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comErasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLCMay 27, 2025 | marketbeat.comMillennium Management LLC Increases Position in Erasca, Inc. (NASDAQ:ERAS)May 26, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comSuvretta Capital Management LLC Has $30.91 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS)May 19, 2025 | marketbeat.comProsight Management LP Trims Holdings in Erasca, Inc. (NASDAQ:ERAS)May 17, 2025 | marketbeat.com5,136,795 Shares in Erasca, Inc. (NASDAQ:ERAS) Bought by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS)May 15, 2025 | marketbeat.comErasca Reports First Quarter 2025 Business Updates and Financial ResultsMay 13, 2025 | globenewswire.comErasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash RunwayMay 13, 2025 | globenewswire.comErasca (ERAS) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comErasca to Present at the Bank of America Securities Health Care ConferenceMay 7, 2025 | globenewswire.comErasca (NASDAQ:ERAS) Earns "Buy" Rating from HC WainwrightMay 2, 2025 | marketbeat.comErasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual MeetingApril 29, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)April 29, 2025 | theglobeandmail.comErasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Buy" from BrokeragesApril 28, 2025 | marketbeat.comMarshall Wace LLP Sells 1,000,700 Shares of Erasca, Inc. (NASDAQ:ERAS)April 27, 2025 | marketbeat.comWalleye Capital LLC Has $348,000 Stock Position in Erasca, Inc. (NASDAQ:ERAS)April 27, 2025 | marketbeat.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.com Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERAS Media Mentions By Week ERAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼0.921.04▲Average Medical News Sentiment ERAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼62▲ERAS Articles Average Week Get the Latest News and Ratings for ERAS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Erasca and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Vericel News Beam Therapeutics News Dyne Therapeutics News Apogee Therapeutics News Twist Bioscience News Travere Therapeutics News Biohaven News Immunocore News Cidara Therapeutics News Aurinia Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access